While highlighting the complexity and heterogeneity of tumor immune microenvironments, the application of single-cell analyses in human cancers has identified recurrent subsets of tumor-associated macrophages (TAMs). Among these, interleukin (IL)-1β+ TAMs – cells with high levels of expression of inflammatory response and tissue repair genes, but with limited capacity to stimulate cytotoxic immunity – are emerging as key drivers of pathogenic inflammation in cancer. In this review we discuss recent literature defining the phenotypical, molecular, and functional properties of IL-1β+ TAMs, as well as their temporal dynamics and spatial organization. Elucidating the biology of these cells across tumor initiation, progression, metastasis, and therapy could inform the design and interpretation of clinical trials targeting IL-1β and/or other inflammatory factors in cancer immunotherapy.

IL-1β+ macrophages and the control of pathogenic inflammation in cancer / Caronni, N.; La Terza, F.; Frosio, L.; Ostuni, R.. - In: TRENDS IN IMMUNOLOGY. - ISSN 1471-4906. - 46:5(2025), pp. 403-415. [10.1016/j.it.2025.03.001]

IL-1β+ macrophages and the control of pathogenic inflammation in cancer

Frosio L.
Penultimo
;
Ostuni R.
Ultimo
2025-01-01

Abstract

While highlighting the complexity and heterogeneity of tumor immune microenvironments, the application of single-cell analyses in human cancers has identified recurrent subsets of tumor-associated macrophages (TAMs). Among these, interleukin (IL)-1β+ TAMs – cells with high levels of expression of inflammatory response and tissue repair genes, but with limited capacity to stimulate cytotoxic immunity – are emerging as key drivers of pathogenic inflammation in cancer. In this review we discuss recent literature defining the phenotypical, molecular, and functional properties of IL-1β+ TAMs, as well as their temporal dynamics and spatial organization. Elucidating the biology of these cells across tumor initiation, progression, metastasis, and therapy could inform the design and interpretation of clinical trials targeting IL-1β and/or other inflammatory factors in cancer immunotherapy.
2025
cancer
inflammation
interleukin 1
macrophages
tumor microenvironment
File in questo prodotto:
File Dimensione Formato  
PIIS1471490625000596.pdf

solo gestori archivio

Tipologia: PDF editoriale (versione pubblicata dall'editore)
Licenza: Tutti i diritti riservati
Dimensione 1.63 MB
Formato Adobe PDF
1.63 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/190899
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 15
social impact